Eric Leip
Overview
Explore the profile of Eric Leip including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gambacorti-Passerini C, Brummendorf T, Abruzzese E, Kelly K, Oehler V, Garcia-Gutierrez V, et al.
Leukemia
. 2024 Aug;
38(10):2162-2170.
PMID: 39164407
This final analysis from the phase 4 BYOND trial reports outcomes with bosutinib in patients with previously treated chronic myeloid leukemia (CML); 163 patients with CML resistant/intolerant to previous tyrosine...
2.
Tomasson M, Iida S, Niesvizky R, Mohty M, Bahlis N, Martinez-Lopez J, et al.
Hemasphere
. 2024 Jul;
8(7):e136.
PMID: 39055646
No abstract available.
3.
Smith B, Brummendorf T, Roboz G, Gambacorti-Passerini C, Charbonnier A, Viqueira A, et al.
Leuk Res
. 2024 Mar;
139:107481.
PMID: 38484432
The BYOND study evaluated the efficacy and safety of bosutinib 500 mg once daily in patients with chronic myeloid leukemia (CML) resistant/intolerant to prior tyrosine kinase inhibitors (TKIs). These post-hoc...
4.
Lesokhin A, Tomasson M, Arnulf B, Bahlis N, Prince H, Niesvizky R, et al.
Nat Med
. 2023 Aug;
29(9):2259-2267.
PMID: 37582952
Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after...
5.
Cortes J, Lipton J, Kota V, Castagnetti F, Assouline S, Brummendorf T, et al.
Haematologica
. 2023 Jul;
108(12):3454-3459.
PMID: 37439348
No abstract available.
6.
Brummendorf T, Cortes J, Milojkovic D, Gambacorti-Passerini C, Clark R, le Coutre P, et al.
Leukemia
. 2022 Jun;
36(7):1825-1833.
PMID: 35643868
This analysis from the multicenter, open-label, phase 3 BFORE trial reports efficacy and safety of bosutinib in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) after five...
7.
Kota V, Brummendorf T, Gambacorti-Passerini C, Lipton J, Kim D, An F, et al.
Leuk Res
. 2021 Oct;
111:106690.
PMID: 34673442
The recommended starting dose of bosutinib is 500 mg/day for chronic-phase (CP) or accelerated-/blast-phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) resistant/intolerant to prior therapy. However, some patients may require...
8.
Muresan B, Mamolo C, Cappelleri J, Leip E, Viqueira A, Heeg B
Curr Med Res Opin
. 2021 Mar;
37(5):801-809.
PMID: 33733983
Objective: Bosutinib, nilotinib and dasatinib are approved for the treatment of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). In the absence of head-to-head comparisons between second-generation tyrosine kinase...
9.
Cortes J, Kantarjian H, Mauro M, An F, Nick S, Leip E, et al.
Eur J Haematol
. 2021 Feb;
106(6):808-820.
PMID: 33638218
Introduction: Long-term follow-up (≥4 years) demonstrated a low incidence of cardiac and vascular treatment-emergent adverse events (TEAEs) with bosutinib treatment. We evaluated cardiac, vascular, hypertension, and effusion TEAEs after ≥ ...
10.
Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen B, Brummendorf T, Smith B, et al.
Leukemia
. 2020 Jun;
34(8):2125-2137.
PMID: 32572189
Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) phase CML after prior treatment...